Increased Wild-Type N-Ras Activation by Neurofibromin Down-Regulation Increases Human Neuroblastoma Stem Cell Malignancy

Genes and Cancer

Volumn 2, Issue 11, 2011, Pages 1034-1043

  Han, Dan ^a   Spengler, Barbara A ^a   Ross, Robert A ^a  

^a FORDHAM UNIVERSITY   (United States)

Author keywords

malignancy; N Ras; neuroblastoma cancer stem cell; neurofibromin

Indexed keywords

CARRIER PROTEIN; N RAS PROTEIN; NEUROFIBROMIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NEUROBLASTOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84868671581     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912443127     Document Type: Article

References (32)

1. Shimada H,Chatten J,Newton WA, et al.Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.J Natl Cancer Inst. 1984;73:405-16.
2. Walton JD,Kattan DR,Thomas SK, et al.Characteristics of stem cells from human neuroblastoma cell lines and in tumors.Neoplasia. 2004;6:838-45.
3. Brodeur GM,Seeger RC,Schwab M,Varmus HE,Bishop JM.Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.Science. 1984;224:1121-4.
4. Land H,Parada LF,Weinberg RA.Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.Nature. 1983;304:596-602.
5. Bos JL.The ras gene family and human carcinogenesis.Mutat Res. 1998;195:255-71.
6. Moley JF,Brother MB,Wells SA,Spengler BA,Biedler JL,Brodeur GM.Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers.Cancer Res. 1991;51:1596-9.
7. Burchill SA,Berry PA,Bradbury FM,Lewis IJ.Contrasting level of p21ras activation and expression of neurofibromin in peripheral primitive neuroectodermal tumor and neuroblastoma cells, and their response to retinoic acid.J Neurol Sci. 1998;157:129-37.
8. Quinlan MQ,Settleman J.Isoform-specific ras functions in development and cancer.Future Oncol. 2009;5:105-16.
9. Malumbres M,Barbacid M.RAS oncogenes: the first 30 years.Nat Rev Cancer. 2003;3:459-65.
10. The I,Murthy AE,Hannigan GE, et al.Neurofibromatosis type 1 gene mutations in neuroblastoma.Nat Genet. 1993;3:62-6.
11. Yohay K.Neurofibromatosis type 1 and associated malignancies.Curr Neurol Neurosci Rep. 2009;9:247-53.
12. Hölzel M,Huang S,Koster J, et al.NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.Cell. 2010;142:218-29.
13. Omerovic J,Hammond DE,Clague MJ,Prior IA.Ras isoform abundance and signaling in human cancer cell lines.Oncogene. 2008;27:2754-62.
14. Ross RA,Spengler BA,Domènech C,Porubcin M,Rettig WJ,Biedler JL.Human neuroblastoma I-type cells are malignant neural crest stem cells.Cell Growth Differ. 1995;6:449-56.
15. Feig LA.Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases.Nat Cell Biol. 1999;1:E25-7.
16. Cichowski K,Santiago S,Jardim M,Johnson BW,Jacks T.Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.Genes Dev. 2003;17:449-54.
17. Mangoura D,Sun Y,Li C, et al.Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.Oncogene. 2006;25:735-45.
18. Leondaritis G,Petrikkos L,Mangoura D.Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation.J Neurochem. 2009;109:573-83.
19. Gotoh N.Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells.Curr Stem Cell Res Ther. 2009;4:9-15.
20. Tsuneoka M,Mekada E.Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras.Oncogene. 2000;19:115-23.
21. Downward J.Targeting RAS signalling pathways in cancer therapy.Nat Rev Cancer. 2003;3:11-22.
22. Korf BR.Malignancy in neurofibromatosis type 1.Oncologist. 2000;5:477-85.
23. Gutmann DH,Wood D,Collins F.Identification of the neurofibromatosis type 1 gene product.Proc Natl Acad Sci U S A. 1991;88:9658-62.
24. McGillicuddy L,Fromm J,Hollstein P, et al.Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.Cancer Cell. 2009;16:44-54.
25. Fernández-Medarde A,Santos E.Ras in cancer and developmental diseases.Genes Cancer. 2011;2:344-58.
26. Dean M,Fojo T,Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer. 2005;5:275-84.
27. Rich JN.Cancer stem cells in radiation resistance.Cancer Res. 2007;67:8980-4.
28. Reynolds CP,Biedler JL,Spengler BA, et al.Characterization of human neuroblastoma cell lines established before and after therapy.J Natl Cancer Inst. 1986;76:375-87.
29. Rettig WJ,Spengler BA,Garin Chesa P,Old LJ,Biedler JL.Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants.Cancer Res. 1987;47:1383-9.
30. Ciccarone V,Spengler BA,Meyers MB,Biedler JL,Ross RA.Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.Cancer Res. 1989;49:219-25.
31. Spengler BA,Lazarova DL,Ross RA,Biedler JL.Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.Oncol Res. 1997;9:467-76.
32. Wu WT,Chi KH,Ho FM,Tsao WC,Lin WW.Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition.Biochem J. 2004;379:587-93.